Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2020 - 2026)

Monte Rosa Therapeutics' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 1132.16% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.6 million (down 96.78% YoY), while the FY2025 annual figure was -$604000.0, down 100.72% from the prior year.
• Other Working Capital Changes was $2.9 million for Q1 2026 at Monte Rosa Therapeutics, up from $177000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $78.4 million in Q4 2024 to a low of -$6.9 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged $5.3 million across 5 years, with a median of $151000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes plunged 2360.66% in 2023, then jumped 7383.01% in 2024.
• A 5-year view of Other Working Capital Changes shows it stood at -$163000.0 in 2022, then tumbled by 560.74% to -$1.1 million in 2023, then surged by 7383.01% to $78.4 million in 2024, then tumbled by 99.77% to $177000.0 in 2025, then jumped by 1550.28% to $2.9 million in 2026.
• The last three Other Working Capital Changes figures came in at $2.9 million (Q1 2026), $177000.0 (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.